Chemotherapy for advanced non-small-cell lung cancer patients with poor performance

References

• Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J. Thorac. Oncol.3(8), 819–831 (2008).
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. J. Med.311(7010), 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer. NCCN Clinical Practice Guidelines in Oncology™ (Version 2) National Comprehensive Cancer Network, PA, USA (2010).
   Google Scholar
• D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v116–v119 (2010).
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol.5(6), 649–655 (1982).
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J. Thorac. Oncol.3(2), 125–129 (2008).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Rossi A, Palazzolo G, Colantuoni G, Rossi E. Management of unfit older patients with advanced NSCLC. Cancer Treat. Rev.35(6), 517–521 (2009).
   Google Scholar
• Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J. Clin. Oncol.4(1), 14–22 (1986).
   PubMed Web of Science ®Google Scholar
• Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br. J. Cancer83(4), 447–453 (2000).
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer27(3), 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Gridelli C. The ELVIS trial: a Phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist6(Suppl. 1), 4–7 (2001).
   PubMed Web of Science ®Google Scholar
• Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst.92(13), 1074–1080 (2000).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Morère JF, Bréchot JM, Westeel V et al. Randomized Phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer DOI: 10.1016/j.lungcan.2010.03.003 (2010) (Epub ahead of print).
   Google Scholar
• Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol.15(3), 419–426 (2004).
   PubMed Web of Science ®Google Scholar
• Quoix EA, Westeel V, Pichon E et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized Phase III study in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.28(7 Suppl.), (2010) (Abstract 2).
   Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim SW, Suh C, Han YH, Lee JS. Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-010-1280-6 (2010) (Epub ahead of print).
   Google Scholar
• Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol.25(7), 760–766 (2007).
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Axelrod R, Thomas S et al. Randomized Phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol.26(6), 863–869 (2008).
   PubMedGoogle Scholar
• Goss G, Ferry D, Wierzbicki R et al. Randomized Phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J. Clin. Oncol.27(13), 2253–2260 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol.27(9), 1394–1400 (2009).
   PubMed Web of Science ®Google Scholar
• Lin CC, Yang CH. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Target. Oncol.4(1), 37–44 (2009).
   PubMedGoogle Scholar
• Bang Y, Shaw AT, Camidge DR et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol.28(7 Suppl.), (2010) (Abstract 3).
   Google Scholar
• Lilenbaum R, Villaflor VM, Langer C et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J. Thorac. Oncol.4(7), 869–874 (2009).
   Google Scholar